Capricor Therapeutics Inc. (CAPR) 3.8500 $CAPR
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
GlobeNewswire - Wed Jul 16, 6:59AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today encouraging analysis of the completion of its MRI data at the six-month time point from Capricor's Phase I ALLSTAR trial.
Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
GlobeNewswire - Mon Jun 23, 8:03AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Linda Marbán, President and CEO, will present during a panel at the first, all-day Regenerative Medicine Forum organized by the California Institute for Regenerative Medicine (CIRM), in association with the Alliance for Regenerative Medicine (ARM) and the International Society for Stem Cell Research (ISSCR). The Regenerative Medicine Forum will take place on Wednesday, June 25, 2014 during the BIO International Convention being held June 23-26, 2014 in San Diego, California.
Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
GlobeNewswire - Thu Jun 19, 12:28PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Rachel Ruckdeschel Smith, Ph.D., Vice President of Research and Development at Capricor, participated in a panel discussion on the regulation of therapeutic products derived from human stem cells at the DIA 2014 50 Annual Meeting, being held June 15-19, 2014 in San Diego, California.
Capricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
GlobeNewswire - Wed May 28, 1:37PM CDT
Identifies Exosomes Originating From Cardiosphere-Derived Cells (CDCs) as Key Mediators of Myocardial Regeneration
Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
GlobeNewswire - Fri Mar 28, 12:42PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marbán, M.D., Ph.D., will present at the American College of Cardiology 63 Annual Scientific Session and Expo, taking place March 29-31, 2014 in Washington, DC. Dr. Marbán's presentation will highlight positive data demonstrating that the Phase I portion of the Company's ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) Phase I/II trial met its primary endpoint of safety.
Capricor Therapeutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Mar 10, 1:11PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that Chief Executive Officer Dr. Linda Marbán is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 in Dana Point, Calif., and the Alliance for Regenerative Medicine's 2 Annual Regen Med Investor Day on March 26, 2014 in New York, N.Y.
Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
GlobeNewswire - Mon Jan 06, 7:30AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of $12.5 million from Janssen.
Capricor Therapeutics Announces Ticker Symbol Change to CAPR
Business Wire - Fri Dec 20, 5:00AM CST
Capricor Therapeutics, Inc. (OTCBB: CAPR), a diversified heart failure biotechnology company, today announced that, effective today, the Company's common stock commences trading on the OTC Markets under the new symbol "CAPR." The previous trading symbol was "NLTXD." The ticker symbol change follows the recently completed merger between Capricor, Inc. and Nile Therapeutics, Inc.
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
GlobeNewswire - Wed Jul 16, 6:59AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today encouraging analysis of the completion of its MRI data at the six-month time point from Capricor's Phase I ALLSTAR trial.
Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
GlobeNewswire - Mon Jun 23, 8:03AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Linda Marbán, President and CEO, will present during a panel at the first, all-day Regenerative Medicine Forum organized by the California Institute for Regenerative Medicine (CIRM), in association with the Alliance for Regenerative Medicine (ARM) and the International Society for Stem Cell Research (ISSCR). The Regenerative Medicine Forum will take place on Wednesday, June 25, 2014 during the BIO International Convention being held June 23-26, 2014 in San Diego, California.
Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
GlobeNewswire - Thu Jun 19, 12:28PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Rachel Ruckdeschel Smith, Ph.D., Vice President of Research and Development at Capricor, participated in a panel discussion on the regulation of therapeutic products derived from human stem cells at the DIA 2014 50 Annual Meeting, being held June 15-19, 2014 in San Diego, California.
Capricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
GlobeNewswire - Wed May 28, 1:37PM CDT
Identifies Exosomes Originating From Cardiosphere-Derived Cells (CDCs) as Key Mediators of Myocardial Regeneration
Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
GlobeNewswire - Fri Mar 28, 12:42PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marbán, M.D., Ph.D., will present at the American College of Cardiology 63 Annual Scientific Session and Expo, taking place March 29-31, 2014 in Washington, DC. Dr. Marbán's presentation will highlight positive data demonstrating that the Phase I portion of the Company's ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) Phase I/II trial met its primary endpoint of safety.
Capricor Therapeutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Mar 10, 1:11PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that Chief Executive Officer Dr. Linda Marbán is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 in Dana Point, Calif., and the Alliance for Regenerative Medicine's 2 Annual Regen Med Investor Day on March 26, 2014 in New York, N.Y.
Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
GlobeNewswire - Mon Jan 06, 7:30AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of $12.5 million from Janssen.
Capricor Therapeutics Announces Ticker Symbol Change to CAPR
Business Wire - Fri Dec 20, 5:00AM CST
Capricor Therapeutics, Inc. (OTCBB: CAPR), a diversified heart failure biotechnology company, today announced that, effective today, the Company's common stock commences trading on the OTC Markets under the new symbol "CAPR." The previous trading symbol was "NLTXD." The ticker symbol change follows the recently completed merger between Capricor, Inc. and Nile Therapeutics, Inc.
